Immunoprotein is an immunologically active protein, which provides immunity against pathogenic organisms or substances. These proteins form the integrated body system of tissues, organs, cells, or cell products that neutralize antigens. They enable the diagnosis of various diseases, such as cardiovascular, oncology, infectious diseases, and others, as they display an abnormal increase in their concentration when in a diseased state. Increase in incidence & prevalence of chronic diseases, rise in geriatric population, and growth in demand for early diagnostic services drive the market growth. However, complex regulatory framework for immunoprotein diagnostic testing limits the growth. The global immunoprotein diagnostic testing market is accounted for $16,485 million in 2016, and is estimated to reach $27,290 million by 2022, growing at a CAGR of 7.4% during the analysis period (2017–2023). Research Beam Model: Research Beam Product ID: 143330 5370 USD New
Immunoprotein Diagnostic Testing Market by Technology (Radioimmunoassay, Immunoturbidity Assay, Chemiluminescence Assay, Immunoprotein Electrophoresis, Enzyme-Based Immunoassay, and Immunofluorescence Assay), by Type (C - reactive Protein Diagnostic Test, Complement System Protein Diagnostic Test, Prealbumin Diagnostic Test, Haptoglobin Diagnostic Test, Immunoglobulin Diagnostic Test, and Free Light Chain Diagnostic Test), and by Application (Autoimmune Disease Testing, Infectious Disease Testing, Allergy Testing, Endocrine Testing, Oncology Testing, and Toxicology Testing) - Global Opportunity Analysis and Industry Forecast, 2016-2023
 

Immunoprotein Diagnostic Testing Market by Technology (Radioimmunoassay, Immunoturbidity Assay, Chemiluminescence Assay, Immunoprotein Electrophoresis, Enzyme-Based Immunoassay, and Immunofluorescence Assay), by Type (C - reactive Protein Diagnostic Test, Complement System Protein Diagnostic Test, Prealbumin Diagnostic Test, Haptoglobin Diagnostic Test, Immunoglobulin Diagnostic Test, and Free Light Chain Diagnostic Test), and by Application (Autoimmune Disease Testing, Infectious Disease Testing, Allergy Testing, Endocrine Testing, Oncology Testing, and Toxicology Testing) - Global Opportunity Analysis and Industry Forecast, 2016-2023

Immunoprotein Diagnostic Testing Market by Technology (Radioimmunoassay, Immunoturbidity Assay, Chemiluminescence Assay, Immunoprotein Electrophoresis

Category : Healthcare
Published On : April  2017
Pages : 199

request-discount


TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

Immunoprotein is an immunologically active protein, which provides immunity against pathogenic organisms or substances. These proteins form the integrated body system of tissues, organs, cells, or cell products that neutralize antigens. They enable the diagnosis of various diseases, such as cardiovascular, oncology, infectious diseases, and others, as they display an abnormal increase in their concentration when in a diseased state. Increase in incidence & prevalence of chronic diseases, rise in geriatric population, and growth in demand for early diagnostic services drive the market growth. However, complex regulatory framework for immunoprotein diagnostic testing limits the growth. The global immunoprotein diagnostic testing market is accounted for $16,485 million in 2016, and is estimated to reach $27,290 million by 2022, growing at a CAGR of 7.4% during the analysis period (2017-2023).

The market is segmented on the basis of type, application, technology, and geography. By type, the market is categorized into C-reactive protein diagnostic test, complement system protein diagnostic test, prealbumin diagnostic test, haptoglobin diagnostic test, immunoglobulin diagnostic test, free light chain diagnostic test, and others. Applications covered in the study include autoimmune disease testing, infectious disease testing, allergy testing, endocrine testing, oncology testing, toxicology testing, and others. Based on technology, it is classified into radioimmunoassay, immunoturbidity assay, chemiluminescence assay, immunoprotein electrophoresis, enzyme-based immunoassay, immunofluorescence assay, and others. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY MARKET BENEFITS:

  • The study provides an in-depth analysis of the global immunoprotein diagnostic testing market with current trends and future estimations to elucidate the investment pockets.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.
  • The report provides a quantitative analysis for the period of 2016-2023, which enables stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of different segments facilitates to understand the various products of the market.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.

KEY MARKET SEGMENT:

By Technology

  • Radioimmunoassay
  • Immunoturbidity Assay
  • Chemiluminescence Assay
  • Immunoprotein Electrophoresis
  • Enzyme-Based Immunoassay
  • Immunofluorescence Assay
  • Others

By Type

  • C-reactive Protein Diagnostic Test
  • Complement System Protein Diagnostic Test
  • Prealbumin Diagnostic Test
  • Haptoglobin Diagnostic Test
  • Immunoglobulin Diagnostic Test
  • Free Light Chain Diagnostic Test
  • Others

By Application

  • Autoimmune Testing
  • Infectious Disease Testing
  • Allergy Testing
  • Endocrine Testing
  • Oncology Testing
  • Toxicology Testing
  • Others

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • Others
  • LAMEA
    • Latin America
    • Middle East
    • Africa

List of players profiled in the report

  • Abbott Laboratories
  • Abcam PLC
  • Bio-Rad Laboratories
  • Danaher Corporation
  • Diasorin
  • Enzo Life Sciences
  • Ortho Clinical Diagnostics
  • Roche Diagnostics
  • Siemens Healthcare
  • Thermo Fisher Scientific

List of other players (These companies are not profiled in the report and same can be done on demand)

  • Affymetrix
  • Alere
  • bioMérieux
  • ORGENTEC Diagnostika
  • Sekisui Diagnostics
  • IBL International
  • ImmunoDX
  • Quidel Corporation
  • Trinity Biotech

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENT
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. TOP PLAYERS POSITIONING, 2016
3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Increase in geriatric population and surge in incidence and prevalence of chronic diseases
3.5.1.2. Increase in government expenditure in the healthcare sector

3.5.2. Restraint

3.5.2.1. Complex regulatory framework

3.5.3. Opportunity

3.5.3.1. Lucrative opportunities from emerging economies

CHAPTER 4 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. RADIOIMMUNOASSAY

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. IMMUNOTURBIDITY ASSAY

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. CHEMILUMINESCENCE ASSAY

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. IMMUNOPROTEIN ELECTROPHORESIS

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. ENZYME-BASED IMMUNOASSAY

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

4.7. IMMUNOFLUORESCENCE ASSAY

4.7.1. Key market trends
4.7.2. Key growth factors and opportunities
4.7.3. Market size and forecast

4.8. OTHER TECHNOLOGY

4.8.1. Key market trends
4.8.2. Key growth factors and opportunities
4.8.3. Market size and forecast

CHAPTER 5 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. C-REACTIVE PROTEIN DIAGNOSTIC TEST

5.2.1. Market size and forecast

5.3. COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TEST

5.3.1. Market size and forecast

5.4. PREALBUMIN DIAGNOSTIC TEST

5.4.1. Market size and forecast

5.5. HAPTOGLOBIN DIAGNOSTIC TEST

5.5.1. Market size and forecast

5.6. IMMUNOGLOBULIN DIAGNOSTIC TEST

5.6.1. Market size and forecast

5.7. FREE LIGHT CHAIN DIAGNOSTIC TEST

5.7.1. Market size and forecast

5.8. OTHER IMMUNOPROTEIN DIAGNOSTIC TEST

5.8.1. Market size and forecast

CHAPTER 6 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. AUTOIMMUNE TESTING

6.2.1. Market size and forecast

6.3. INFECTIOUS DISEASE TESTING

6.3.1. Market size and forecast

6.4. ALLERGY TESTING

6.4.1. Market size and forecast

6.5. ENDOCRINE DISEASE TESTING

6.5.1. Market size and forecast

6.6. ONCOLOGY TESTING

6.6.1. Market size and forecast

6.7. TOXICOLOGY TESTING

6.7.1. Market size and forecast

6.8. OTHERS

6.8.1. Market size and forecast

CHAPTER 7 IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. India market size and forecast
7.4.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Latin America market size and forecast
7.5.5. Middle East market size and forecast
7.5.6. Africa market size and forecast

CHAPTER 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. ABCAM PLC

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. BIO-RAD LABORATORIES, INC.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. DANAHER CORPORATION

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segment
8.4.4. Product portfolio
8.4.5. Business performance

8.5. DIASORIN S.P.A

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. ENZO BIOCHEM, INC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Operating business segments
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. F. HOFFMANN-LA ROCHE AG (ROCHE DIAGNOSTICS)

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. ORTHO CLINICAL DIAGNOSTICS

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Key strategic moves and developments

8.9. SIEMENS AKTIENGESELLSCHAFT

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating segments
8.9.4. Product portfolio
8.9.5. Business performance

8.10. THERMO FISHER SCIENTIFIC INC

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

LIST OF TABLES

TABLE 1. GLOBAL INCIDENCE RATES OF DISEASES
TABLE 2. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 3. RADIOIMMUNOASSAY BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 4. IMMUNOTURBIDITY ASSAY BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 5. CHEMILUMINESCENCE ASSAY BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 6. IMMUNOPROTEIN ELECTROPHORESIS BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 7. ENZYME IMMUNOASSAY BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 8. IMMUNOFLUORESCENCE ASSAY BASED IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 9. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHER TECHNOLOGY, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 10. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 11. C-REACTIVE PROTEIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 12. COMPLEMENT SYSTEM PROTEIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 13. PREALBUMIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 14. HAPTOGLOBIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 15. IMMUNOGLOBULIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 16. FREE LIGHT CHAIN DIAGNOSTIC TESTS MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 17. OTHER IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 18. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 19. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR AUTOIMMUNE DISEASES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 20. INFECTIOUS DISEASES CAUSED BY SPECIFIC HOSTS
TABLE 21. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR INFECTIOUS DISEASES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 22. TYPES OF ALLERGY AND THEIR PREVALENCE
TABLE 23. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ALLERGY, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 24. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ENDOCRINE DISEASES, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 25. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR ONCOLOGY, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 26. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR TOXICOLOGY TESTING, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 27. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET FOR OTHER APPLICATIONS, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 28. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023 ($MILLION)
TABLE 29. NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 30. NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 31. NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 32. NORTH AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 33. EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 34. EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 35. EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 36. EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 37. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY COUNTRY, 2016-2023 ($MILLION)
TABLE 38. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 39. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 40. ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 41. LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY REGION, 2016-2023 ($MILLION)
TABLE 42. LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TECHNOLOGY, 2016-2023 ($MILLION)
TABLE 43. LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY TYPE, 2016-2023 ($MILLION)
TABLE 44. LAMEA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY APPLICATION, 2016-2023 ($MILLION)
TABLE 45. ABBOTT: COMPANY SNAPSHOT
TABLE 46. ABBOTT: OPERATING SEGMENTS
TABLE 47. ABBOTT: PRODUCT PORTFOLIO
TABLE 48. ABCAM: COMPANY SNAPSHOT
TABLE 49. ABCAM: OPERATING SEGMENTS
TABLE 50. ABCAM: OPERATING SEGMENTS
TABLE 51. BIO-RAD: COMPANY SNAPSHOT
TABLE 52. BIO-RAD: OPERATING SEGMENTS
TABLE 53. BIO-RAD: PRODUCT PORTFOLIO
TABLE 54. DANAHER: COMPANY SNAPSHOT
TABLE 55. DANAHER: OPERATING SEGMENTS
TABLE 56. DANAHER: PRODUCT PORTFOLIO
TABLE 57. DIOSORIN: COMPANY SNAPSHOT
TABLE 58. DIOSORIN: OPERATING SEGMENTS
TABLE 59. DIOSORIN: PRODUCT PORTFOLIO
TABLE 60. ENZO: SNAPSHOT
TABLE 61. ENZO: OPERATING SEGMENTS
TABLE 62. ENZO: PRODUCT PORTFOLIO
TABLE 63. ROCHE: COMPANY SNAPSHOT
TABLE 64. ROCHE: OPERATING SEGMENT
TABLE 65. ROCHE: PRODUCT PORTFOLIO
TABLE 66. ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT
TABLE 67. ORTHO CLINICAL DIAGNOSTICS: OPERATING SEGMENTS
TABLE 68. ORTHO CLINICAL DIAGNOSTICS: PRODUCT PORTFOLIO
TABLE 69. SIEMENS: COMPANY SNAPSHOT
TABLE 70. SEIMENS: OPERATING SEGMENTS
TABLE 71. SIEMENS: PRODUCT PORTFOLIO
TABLE 72. THERMO FISHER: COMPANY SNAPSHOT
TABLE 73. THERMO FISHER: OPERATING SEGMENTS
TABLE 74. THERMO FISHER: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 1. GLOBAL IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023
FIGURE 2. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, BY GEOGRAPHY, 2016-2023
FIGURE 3. MARKET SEGMENTATION
FIGURE 4. TOP INVESTMENT POCKETS
FIGURE 5. TOP WINNING STRATEGIES, 2014-2016 (%)
FIGURE 6. TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 7. TOP PLAYER POSITIONING: IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016
FIGURE 8. INCIDENCE RATE OF CHRONIC DISEASES, 1995-2030
FIGURE 9. U.S. HEALTHCARE EXPENDITURE PER PERSON (USD)
FIGURE 10. RISING GDP OF MANY COUNTRIES ($TRILLION)
FIGURE 11. NUMBER OF DIAGNOSED CANCER CASES WORLDWIDE
FIGURE 12. GLOBAL COMMON CANCER STATISTICS, 2012-2030
FIGURE 13. SPECIFIC ILLICIT DRUG DEPENDENCE OR ABUSE IN THE U.S., 2013
FIGURE 14. U.S. IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 15. CANADA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 16. MEXICO IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 17. GERMANY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 18. FRANCE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 19. UK IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 20. ITALY IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 21. SPAIN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 22. REST OF EUROPE IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 23. JAPAN IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 24. CHINA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 25. INDIA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 26. REST OF ASIA-PACIFIC IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 27. LATIN AMERICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 28. MIDDLE EAST IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 29. AFRICA IMMUNOPROTEIN DIAGNOSTIC TESTING MARKET, 2016-2023 ($MILLION)
FIGURE 30. ABBOTT: REVENUE, 2014-2016 ($MILLION)
FIGURE 31. ABBOTT: REVENUE BY SEGMENT, 2016 (%)
FIGURE 32. ABBOTT: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 33. ABCAM: REVENUE, 2014-2016 ($MILLION)
FIGURE 34. ABCAM: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 35. BIO-RAD: REVENUE, 2014-2016 ($MILLION)
FIGURE 36. BIO-RAD: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 37. BIO-RAD: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 38. DANAHER: REVENUE, 2014-2016 ($MILLION)
FIGURE 39. DANAHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 40. DANAHER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 41. DIOSORIN: REVENUE, 2013-2015 ($MILLION)
FIGURE 42. DIOSORIN: REVENUE BY GEOGRAPHY, 2015 (%)
FIGURE 43. ENZO: REVENUE, 2014-2016 ($MILLION)
FIGURE 44. ENZO: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 45. ENZO: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 46. ROCHE: REVENUE, 2014-2016 ($MILLION)
FIGURE 47. ROCHE: REVENUE BY SEGMENT, 2016 (%)
FIGURE 48. ROCHE: REVENUE BY GEOGRAPHY, 2016 (%)
FIGURE 49. SIEMENS: REVENUE, 2014-2016 ($MILLION)
FIGURE 50. SIEMENS: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 51. SIEMENS: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 52. THERMO FISHER: REVENUE, 2014-2016 ($MILLION)
FIGURE 53. THERMO FISHER: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 54. THERMO FISHER: REVENUE SHARE BY GEOGRAPHY, 2016 (%)

Enquiry Before Buy